ArticleXenotransplantation
Porcine Expanded Potential Stem Cells as a Versatile Platform for Multiplex Genome Editing and Immunophenotyping in Xenotransplantation.
Article in Xenotransplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Xenotransplantation utilizing pig donors offers a promising solution to organ shortages, but immune incompatibilities across species remain a major challenge. Current reliance on porcine primary fibroblasts for genome editing is limited by low inefficiency in complex gene editing and difficulties in immunophenotyping edited cells. In this study, we demonstrate that porcine expanded potential stem cells (pEPSCs), derived from preimplantation embryos, provide a robust and versatile platform for generating donor cells for xenotransplantation. These pluripotent cells can differentiate into both embryonic and extraembryonic lineages, maintain genetic stability through multiple edits, and enable precise genome modifications. We performed multiple gene knockouts in pEPSCs targeting key immune rejection genes and precisely inserted a genetic cassette to facilitate streamlined introduction of human cDNAs via cassette exchange. The engineered pEPSCs retained their pluripotency and stability even after multiple rounds of genome editing. When differentiated into endothelial cells, they exhibited high immunogenicity, serving as a rapid and quantitative platform for immune response assessment. Importantly, the edited endothelial cells exhibited substantially reduced immunogenicity, confirming the functional impact of the genetic modifications. Although we have not yet generated live pigs from these gene-edited pEPSCs via somatic cell nuclear transfer (SCNT), our findings establish pEPSCs as a novel and improved platform for generating genetically engineered pig donors and for functionally evaluating genetic modifications, thereby advancing the prospects of xenotransplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.